Telix Reports Third Quarter 2026 Financial Performance
Key Highlights
- ➤Group revenue $245 million, up 19% year over year in Q3 2026
- ➤Precision Medicine revenue $201 million, up 30% year over year
- ➤FDA approved Pixclara for glioma imaging, with first commercial doses in September
- ➤Telix agreed to merge with ITM for $1.65 billion upfront consideration
- ➤FY 2026 revenue and other income expected to exceed $1 billion
Expert Statements
Christian Behrenbruch, Managing Director and Group CEO of Telix Pharmaceuticals
“Demand for both Gozellix and Illuccix remained strong during the quarter, with U.S. dose volumes increasing 1% quarter-over-quarter, in line with our expectations and reflecting expected summer seasonality.”
Christian Behrenbruch, Managing Director and Group CEO of Telix Pharmaceuticals
“We are pleased by the strong September exit run rate, supporting our confidence in delivering over 25% Precision Medicine revenue growth in 2026.”
Christian Behrenbruch, Managing Director and Group CEO of Telix Pharmaceuticals
“We achieved an important milestone with the FDA approval of Pixclara, expanding our commercial portfolio, establishing a presence in neuro-oncology and further diversifying our revenue base.”
Christian Behrenbruch, Managing Director and Group CEO of Telix Pharmaceuticals
“During the quarter, we announced a transformative merger with ITM, creating a leading vertically integrated radiopharmaceutical company with one of the industry's broadest therapeutic pipelines and expanded isotope production and global manufacturing capabilities.”
Christian Behrenbruch, Managing Director and Group CEO of Telix Pharmaceuticals
“This is aligned with our long-term growth strategy reinforcing our ability to reliably serve patients at scale.”
Telix Reports Third Quarter 2026 Financial Performance PR Newswire
MELBOURNE, Australia and INDIANAPOLIS, Oct. 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a financial update on its commercial and operational performance for the quarter ended September 30, 2026 (Q3 2026).
Get started
Create a free account to read the full story.